Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 37th Annual Meeting, highlighting a diverse panel of CD3-binding antibodies for potential cancer treatments. The research includes proof-of-concept studies demonstrating T-cell engagers that effectively kill cancer cells while minimizing cytokine release. The company aims to enhance the development of bispecific antibodies, addressing the challenges of T-cell activation and specificity. AbCellera's advancements underscore its rapid antibody discovery capabilities and potential market impact.
AbCellera (Nasdaq: ABCL) reported impressive Q3 2022 financial results, with total revenue of $101.4 million, up from $5.5 million year-over-year. The company achieved net earnings of $26.6 million, or $0.09 per share, reversing a net loss of ($21.4 million) in Q3 2021. Program starts increased by 33% to a cumulative total of 92, and the number of molecules in clinical trials rose to 7. With a strong cash position of $868 million, AbCellera is well-positioned for future growth in antibody discovery.
AbCellera (Nasdaq: ABCL) announced participation in two major investor conferences. The company will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 3:50 p.m. PT, and at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:30 a.m. PT. Live webcasts will be available on AbCellera's Investor Relations website, with replays following the events. AbCellera is focused on leveraging natural immune systems to discover antibodies for drug development.
AbCellera (NASDAQ: ABCL) announced that Regeneron has advanced a therapeutic antibody candidate discovered in their collaboration into further preclinical development. This partnership, which began in March 2020, utilizes AbCellera's advanced antibody discovery platform alongside Regeneron's VelocImmune® mice technology. The candidate targets a G-protein coupled receptor and marks the first antibody selected for further evaluation in this initiative. AbCellera will receive undisclosed research payments and milestone payments, royalty opportunities on net sales, emphasizing continued growth in its drug development collaborations.
AbCellera (Nasdaq: ABCL) will release its third quarter 2022 financial results on November 8, 2022, followed by an earnings call at 2:00 p.m. PT. The call will be accessible via a live audio webcast on AbCellera’s Investor Relations website. AbCellera specializes in analyzing natural immune systems to discover antibodies for drug development, partnering with a wide array of drug developers to enhance efficiency and tackle complex challenges in the industry.
AbCellera (Nasdaq: ABCL) will present at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8 to 12, 2022. The company’s VP of Translational Research, Bo Barnhart, emphasized the potential of T-cell engagers in oncology, highlighting advances in their CD3 panel and T-cell engager program. The presentation titled 'Streamlining T-cell engager development' is scheduled for November 11, showcasing AbCellera's bispecific engineering technology aimed at overcoming challenges in cancer treatment.
AbCellera (Nasdaq: ABCL) has commenced the second phase of its global headquarters expansion in Vancouver, Canada, with a new 380,000-square-foot tech campus. This facility will enhance lab and office capabilities to support the company's objectives in antibody-based medicine development. The expansion aims to accommodate its growing workforce of over 450 employees and advance its integrated solutions for biopharma partners. The completion of this facility is planned for 2025, following the first phase scheduled for late 2023.
AbCellera (Nasdaq: ABCL) reported Q2 2022 financial results with total revenue of $46 million, a significant increase from $28 million in Q2 2021. The company incurred a net loss of $7 million, up from $2 million in the previous year. Notably, four new programs were initiated, increasing the total program starts by 47% year-over-year to 88. Additionally, AbCellera added six new programs under contract, bringing the total to 164. R&D expenses grew to $26.7 million, while cash reserves amounted to $1.022 billion.
AbCellera (Nasdaq: ABCL) has partnered with Atlas Venture to discover therapeutic antibodies for up to three drug targets. The collaboration allows a stealth-stage company backed by Atlas to develop and commercialize these antibodies, leveraging AbCellera's advanced technology for faster drug discovery. Under the agreement, AbCellera will receive research payments and potential milestone payments, enhancing its revenue generating capabilities. Both companies emphasize a commitment to create impactful medicines efficiently and effectively.
AbCellera (Nasdaq: ABCL) has announced a multi-year partnership with Versant Ventures to discover therapeutic antibodies for various targets. This collaboration builds on previous successful partnerships, enabling three stealth-stage companies under Versant. AbCellera will receive research payments and potential milestone payments, along with royalties on product sales. The partnership aims to enhance the capabilities of small biotech firms, improving their efficiency in developing antibody therapeutics.